Ambarella Introduces CV5 High Performance AI Vision Processor for Single 8K and Multi-Imager AI Cameras
11.1.2021 13:00:00 EET | Business Wire | Press release
Ambarella, Inc. (Nasdaq: AMBA), an AI vision silicon company, today unveiled CV5, an artificial intelligence (AI) vision processor capable of recording 8K video or four 4K video streams. The new system on chip (SoC) will enable the development of intelligent automotive camera systems, consumer cameras (drone, action, and 360°), and robotic cameras. It combines Ambarella’s powerful CVflow AI engine with dual Arm® A76 CPUs to provide the performance necessary for a wide range of AI-based algorithms. Its advanced image signal processor (ISP) can simultaneously process images for both human viewing and machine processing. Fabricated in advanced 5 nm process technology, CV5 consumes under 2 watts of power while encoding full 8K video at 30 frames per second.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005235/en/
Ambarella today unveiled the CV5 AI vision CVflow® 5 nm processor for single 8K and multi-imager AI cameras, setting a new standard for power efficiency with 8K video recording in under 2 watts. The SoC targets intelligent automotive camera systems, consumer cameras (drone, action, and 360°), and robotic cameras. (Photo: Business Wire)
“With the introduction of CV5, Ambarella is defining the next generation of automotive, consumer, and robotic cameras,” said Fermi Wang, CEO of Ambarella. “By combining 8K single-channel and 4K multi-channel recording with the high performance of our CVflow AI engine, we are enabling cameras with the highest-quality imaging and innovative new AI features.”
In automotive video telematics applications, CV5 provides the performance necessary to encode multiple video streams from front ADAS, driver monitoring, cabin monitoring, and side-view cameras. Its CVflow AI engine can simultaneously run advanced driver assistance systems (ADAS) algorithms such as lane departure, and forward collision warning as well as driver monitoring algorithms such as drowsy driver detection. The combination of high-resolution video capture with advanced AI processing enables ADAS cameras to recognize images over long distances and with high accuracy.
The exceptionally low power consumption of the CV5 SoC also makes it an ideal solution for the next generation of high resolution and high frame-rate action, 360°, and virtual reality (VR) cameras, offering 8K recording and playback in very small form factor designs.
In robotic and drone applications, CV5’s CVflow AI engine can accelerate simultaneous localization and mapping (SLAM), path planning, and obstacle detection, and avoidance algorithms for navigation and autonomous operation. For drone-based aerial videography and cinematography, CV5 can simultaneously perform flight control and navigation functions while recording up to 8K resolution video recording at 60 frames per second.
The CV5 SoC shares common SDK and computer vision (CV) tools with Ambarella’s other CVflow SoC families, simplifying development of cameras with multiple price and performance options. A complete set of CV tools helps customers port their own neural networks onto CV5, including a compiler, debugger, and support for industry-standard machine learning frameworks, such as PyTorch™, ONNX™, Caffe™, and TensorFlow™, as well as extensive guidelines for convolutional neural network (CNN) performance optimization.
CV5 SoC key features:
- CVflow architecture with DNN support
- Dual-core Arm® Cortex®-A76 up to 1.6 GHz with NEON™ DSP extensions and FPU
- High-speed SLVS-EC, MIPI-CSI (C/D PHY) interfaces, connecting up to 14 cameras
- Multi-channel ISP with up to 8KP60 throughput
- Native support for RGGB, RCCB, RCCC, RGB-IR, and monochrome sensor formats
- Multi-exposure high dynamic range (HDR) processing
- Real-time, hardware-accelerated fisheye dewarping and lens distortion correction (LDC)
- AVC and HEVC encoding with up to 8KP60 throughput and multiple stream support
- Rich set of interfaces includes 4-lane PCIe, CAN FD, Gigabit Ethernet, USB 3.1 host and device, three SD card controllers, MIPI DSI/CSI-2 and HDMI video outputs
- LPDDR4x / LPDDR5 / LPDDR5x support, 64-bit data bus and up to 32 GB capacity
- Advanced security features, including secure boot with TrustZone® and secure memory, TRNG, OTP, DRAM scrambling and virtualization
- 5 nm process technology
- 16x16 FBGA package with 0.5 mm ball pitch
About Ambarella, Inc.
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power system on chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com
All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications and pricing at any time without notice. © 2021 Ambarella, Inc. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005235/en/
Contact information
Ambarella Contact: www.ambarella.com/about/contact/inquiries
Media Contact: Molly McCarthy, Valley Public Relations, mmccarthy@ambarella.com
Investor Relations Contact: Louis Gerhardy, Ambarella, lgerhardy@ambarella.com, (408) 636-2310
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
